Comparative study of the antioxidant properties of monocarbonyl curcumin analogues C66 and B2BrBC in isoproteranol induced cardiac damage

Antioxidant and anti‐inflammatory effects of the monocarbonyl curcumin analogs B2BRBC and C66 in monocrotaline‐induced right ventricular hypertrophy

“…Hence, we speculate that the lack of capacity in one or several nonenzymatic antioxidant domains is responsible for the observed high lipid peroxidation in the settings of increased enzymatic antioxidant defense in the MCT and MCT + C66 groups. This is supported by our observation that the addition of a stronger antioxidant that is B2BrBC, yielded better inhibition of lipid peroxidation in the current (Figure ) and in a previous experiment involving cardiac hypertrophy . Furthermore, our findings corroborate the reported low antioxidant activity of C66, which was improved by the introduction of Br in its structure …”

“…The same volume of pH‐adjusted physiological saline was injected into the control group of the rats. The 2,6‐bis‐(2‐X‐benzylidene)cyclohexanone derivatives were prepared as previously described, and the rats in the MCT + B2BrBC and MCT + C66 groups received B2BrBC and C66, respectively, at a dose of 20 mg/kg, daily by gavage . Rats in the C and the MCT groups were gavaged with a vehicle only.…”

“…[18,19] Some of these compounds have shown beneficial effects in experimental models in the treatment of cardiovascular diseases including hypertrophy-induced injuries. [19][20][21][22] For example, one of the analogs, (2E,6E)-2,6-bis([2-trifluoromethyl]benzylidene)cyclohexanone (C66) was effective in preventing cardiomyocyte inflammation and apoptosis during diabetic cardiomyopathy [20] and our lab has synthesized and tested a novel symmetric monocarbonyl analog, (2E,6E)-2,6-bis(2-bromobenzylidene)cycloxehanone (B2BrBC), which was effective in preventing isoproterenol-induced cardiac hypertrophy due to its strong antioxidant properties. [22] So far, the therapeutic potential of curcumin analogs in RV hypertrophy following MCT-induced PAH has not been studied.…”

“…[19][20][21][22] For example, one of the analogs, (2E,6E)-2,6-bis([2-trifluoromethyl]benzylidene)cyclohexanone (C66) was effective in preventing cardiomyocyte inflammation and apoptosis during diabetic cardiomyopathy [20] and our lab has synthesized and tested a novel symmetric monocarbonyl analog, (2E,6E)-2,6-bis(2-bromobenzylidene)cycloxehanone (B2BrBC), which was effective in preventing isoproterenol-induced cardiac hypertrophy due to its strong antioxidant properties. [22] So far, the therapeutic potential of curcumin analogs in RV hypertrophy following MCT-induced PAH has not been studied. In this study, we investigated the protective effects of both B2BrBC and C66 At the first day of treatment, monocrotaline (Sigma, St Louis) was administered as a single subcutaneous dose of 60 mg/kg [23] dissolved in 0.5M HCl and pH adjusted to 7.4 with 0.2M NaOH.…”

Curcumin synergistically potentiates the protective effect of sitagliptin against chronic deltamethrin nephrotoxicity in rats: Impact on pro‐inflammatory cytokines and Nrf2/Ho‐1 pathway

“…Some naturally occurring flavonoids appear to have organ defensive capacities against different toxic compounds and can work synergistically with other synthetic or natural compounds, for example, metformin to suppress nephrotoxicity instigated by gentamycin . Curcumin (Cur), a main component of turmeric regularly utilized as a food flavor, is a characteristic polyphenolic flavonoid segregated from the rhizome of the plant Curcuma longa Linné . Cur appears to display different biological functions, antioxidant, anti‐inflammatory, anti‐tumorigenic activities.…”